Articles
- Is Ageing Research Worth It — And Will the Drugs Actually Work?
A critical deep-dive: what the Pace of Ageing data reveals, how epigenetic clocks expose the gap between lifespan and healthspan, where the longevity drug pipeline stands, and why the honest answer is more nuanced than either camp admits.
- Brain-Computer Interfaces 2025: Who Else Deserves Attention Beyond Neuralink?
While Neuralink captures global headlines, China has quietly entered the commercial and clinical reimbursement stage of BCI. A full breakdown of international frontrunners, China's policy landscape, and the industry chain.
- After Resmetirom: The Next Wave of MASH Therapies
A deep dive into the most promising targets and pipelines reshaping the MASH field.